Caution is required when using Upatinib: a comprehensive analysis of its side effects and risk management

Upadacitinib, a selective inhibitor of JAK1, has attracted much attention for its significant efficacy in the treatment of immune diseases such as rheumatoid arthritis, atopic dermatitis (eczema), and ulcerative colitis. However, like other immunosuppressants, while its therapeutic effect, upadatinib is also accompanied by a series of potential side effects and risks. These side effects range from mild discomfort to severe reactions, so regular monitoring and guidance from your doctor are crucial while using upapatinib. The following is a detailed analysis of the main side effects of upadatinib.

1. Rising risk of infection

Upper respiratory tract infections: One of the common side effects of upadacitinib is an increased risk of upper respiratory tract infections, such as the common cold and nasopharyngitis. Due to the suppressive effect of the drug on the immune system, the patient's immune defenses may be reduced. Therefore, if patients develop cough, runny nose, sore throat and other symptoms while taking the medicine, they should report to the doctor in time.

Herpes Zoster: Patients taking upadacitinib, especially those with a history of herpes zoster, are at increased risk of developing herpes zoster. This is because JAK1 inhibitors may weaken the body's resistance to viral infection.

Serious infections: In rare cases, upadacitinib may cause more serious infections, such as pneumonia, skin and soft tissue infections. If patients develop symptoms such as fever, difficulty breathing, or skin redness and swelling during medication, they should seek medical attention immediately and evaluate whether the treatment plan needs to be adjusted.

2. Abnormal reaction of the blood system

Neutropenia: Upadatinib may cause neutropenia, which may reduce a patient's ability to fight infections. Therefore, during medication, doctors usually monitor the patient's blood routine regularly to detect changes in the number of white blood cells and neutrophils. If neutrophil levels decrease significantly, medication may need to be suspended or dosage adjusted.

Anemia and thrombocytopenia: In some cases, upadacitinib may cause anemia or a decrease in the number of platelets. Symptoms of anemia include fatigue, dizziness, and pale skin, while low platelets may increase a patient's risk of bleeding, such as skin bruising or gum bleeding.

3. Risk of abnormal liver function

Elevated liver enzymes: Patients taking upadacitinib may experience an increase in liver function indicators during treatment, mainly increased levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). Although in most cases this change is mild, in rare cases a dose adjustment or medication suspension may be necessary. Therefore, doctors will regularly monitor liver function during treatment to ensure that it is within a safe range.

Risk of jaundice and hepatitis: In rare cases, patients may develop symptoms of jaundice or drug-induced hepatitis, such as yellowing of the skin or whites of the eyes, loss of appetite, etc. If these symptoms occur, stop taking the medicine immediately and seek medical help.

4. Abnormal changes in blood lipid levels

Upadatinib may cause increases in blood lipid levels (such as total cholesterol, low-density lipoproteinLDL, and high-density lipoproteinHDL). This increase is usually most significant within the first few months of treatment. Therefore, doctors will regularly test patients’ blood lipid levels and provide lipid-lowering treatment when necessary.

5. Increased cardiovascular risk

Thrombus formation: Upadatinib may increase the risk of venous thrombosis, including deep vein thrombosis (DVT) and pulmonary embolism (PE). This risk is particularly important in patients with a history of blood clots. If patients experience symptoms such as leg swelling, shortness of breath, or chest pain while taking the medicine, they should seek medical attention immediately.

Cardiovascular Events: Long-term use of upadacitinib may increase the risk of cardiovascular events, such as myocardial infarction and stroke, in some patients. This risk is higher in patients with a history of cardiovascular disease, so cardiovascular risk needs to be assessed before treatment.

6. Discomfort of gastrointestinal symptoms

Common gastrointestinal adverse reactions include nausea, abdominal pain and diarrhea. In most cases, these symptoms are mild and can be relieved by adjusting diet or taking gastrointestinal protective medications. However, if symptoms persist or are severe, you should talk to your doctor to evaluate whether treatment needs to be adjusted.

7. Occurrence of skin reactions

Upadatinib may cause rash, itching and other adverse skin reactions. Although most of these skin reactions are mild, in rare cases severe skin allergic reactions, such as erythema multiforme or drug-induced rash, may occur. In this case, the patient needs to stop taking the medication immediately and seek medical attention.

Upadatinib has shown remarkable efficacy in the treatment of chronic diseases such as atopic dermatitis and rheumatoid arthritis, but the various side effects that may be associated with its use cannot be ignored. In order to obtain the best efficacy and minimize the risks during treatment, patients should strictly follow the doctor's medication instructions and regularly undergo necessary examinations, such as routine blood tests, liver function and blood lipid level testing. At the same time, if patients experience any symptoms of discomfort while taking the medicine, they should report it to the doctor in time and adjust the treatment plan if necessary. Through close doctor-patient communication and regular monitoring, the side effects of upadatinib can be effectively managed, thereby ensuring that patients achieve both efficacy and safety during treatment.